ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Educational Symposium

Hope in ADPKD: Innovation in Therapeutics

November 03, 2022 | 12:45 PM - 01:45 PM

Location: Windermere Ballroom X, Hyatt Regency Orlando

Session Description

Polycystic kidney diseases are a group of renal cystic disorders accompanied by a broad array of extrarenal manifestations. The autosomal dominant form, ADPKD, is primarily caused by mutations in the PKD1 and PKD2 genes encoding for polycystin 1 (PC1) and polycystin 2 (PC2). The encoded proteins regulate differentiation, proliferation, survival, apoptosis, and autophagy in renal tubule epithelial cells. Advances in the understanding of multiple molecular pathways involved in the pathophysiology of ADPKD have led to the development of novel treatments, approved or currently under investigation. The approval of tolvaptan, and in Italy of long-acting release octreotide (octreotide-LAR), represents significant hope in the new therapeutic landscape for ADPKD.

This symposium focuses on recent advances in understanding the pathogenic mechanisms underlying ADPKD, as well as current and emerging therapies to slow its progression.

Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.

Learning Objective(s)

  • Discuss ADPKD risk stratification and selecting patients for therapy
  • Identify emerging and innovative therapies in ADPKD
  • Identify therapies for polycystic liver disease

Learning Pathway(s)

  • Genetic Diseases and Development


  • Marie C. Hogan, MBChB, PhD, FASN


  • Introduction
    12:45 PM - 12:55 PM
    Marie C. Hogan, MBChB, PhD, FASN
  • Diagnosis, Genetic Testing, and Risk Stratification in ADPKD
    12:55 PM - 01:15 PM
    Meyeon Park, MD, FASN
  • Current and Emerging Therapies in ADPKD and Polycystic Liver Disease
    01:15 PM - 01:35 PM
    Fouad T. Chebib, MD, FASN
  • Questions and Answers
    01:35 PM - 01:45 PM